ALPS Advisors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.16M | Buy |
18,497
+158
| +0.9% | +$11K | 0.01% | 555 |
|
|
2025
Q4 | $1.22M | Buy |
18,339
+961
| +6% | +$62.1K | 0.01% | 494 |
|
|
2025
Q3 | $1.17M | Buy |
17,378
+2,037
| +13% | +$161K | 0.01% | 482 |
|
|
2025
Q2 | $1.34M | Sell |
15,341
-1,796
| -10% | -$141K | 0.01% | 429 |
|
|
2025
Q1 | $1.17M | Buy |
17,137
+5,219
| +44% | +$426K | 0.01% | 441 |
|
|
2024
Q4 | $927K | Sell |
11,918
-1,124
| -9% | -$83.2K | 0.01% | 494 |
|
|
2024
Q3 | $874K | Buy |
13,042
+1,247
| +11% | +$102K | 0.01% | 536 |
|
|
2024
Q2 | $1.34M | Buy |
11,795
+599
| +5% | +$75.7K | 0.01% | 400 |
|
|
2024
Q1 | $1.55M | Sell |
11,196
-511
| -4% | -$64.2K | 0.01% | 392 |
|
|
2023
Q4 | $1.45M | Sell |
11,707
-1,170
| -9% | -$120K | 0.01% | 389 |
|
|
2023
Q3 | $1.2M | Buy |
12,877
+763
| +6% | +$86K | 0.01% | 406 |
|
|
2023
Q2 | $1.56M | Sell |
12,114
-1,206
| -9% | -$146K | 0.01% | 363 |
|
|
2023
Q1 | $1.55M | Buy |
13,320
+4,004
| +43% | +$448K | 0.01% | 353 |
|
|
2022
Q4 | $1.05M | Sell |
9,316
-4,563
| -33% | -$501K | 0.01% | 467 |
|
|
2022
Q3 | $1.12M | Sell |
13,879
-4,561
| -25% | -$386K | 0.01% | 439 |
|
|
2022
Q2 | $1.37M | Buy |
18,440
+1,900
| +11% | +$173K | 0.01% | 385 |
|
|
2022
Q1 | $2.12M | Sell |
16,540
-3,384
| -17% | -$370K | 0.02% | 198 |
|
|
2021
Q4 | $2.67M | Sell |
19,924
-520
| -3% | -$74.7K | 0.03% | 218 |
|
|
2021
Q3 | $2.79M | Sell |
20,444
-2,000
| -9% | -$252K | 0.03% | 229 |
|
|
2021
Q2 | $2.4M | Sell |
22,444
-184
| -0.8% | -$17.7K | 0.02% | 270 |
|
|
2021
Q1 | $2.03M | Buy |
22,628
+784
| +4% | +$73.6K | 0.02% | 290 |
|
|
2020
Q4 | $2.02M | Buy |
21,844
+1,644
| +8% | +$147K | 0.02% | 277 |
|
|
2020
Q3 | $2.08M | Buy |
20,200
+676
| +3% | +$70.6K | 0.03% | 231 |
|
|
2020
Q2 | $1.98M | Buy |
19,524
+4,396
| +29% | +$393K | 0.03% | 238 |
|
|
2020
Q1 | $1.02M | Buy |
15,128
+124
| +0.8% | +$7.72K | 0.02% | 271 |
|
|
2019
Q4 | $820K | Sell |
15,004
-3,732
| -20% | -$177K | 0.01% | 379 |
|
|
2019
Q3 | $699K | Sell |
18,736
-380
| -2% | -$14.8K | 0.01% | 391 |
|
|
2019
Q2 | $716K | Buy |
19,116
+4,480
| +31% | +$141K | 0.01% | 431 |
|
|
2019
Q1 | $436K | Buy |
14,636
+504
| +4% | +$17.7K | ﹤0.01% | 567 |
|
|
2018
Q4 | $423K | Sell |
14,132
-152
| -1% | -$4.82K | ﹤0.01% | 549 |
|
|
2018
Q3 | $511K | Buy |
14,284
+1,064
| +8% | +$33K | ﹤0.01% | 580 |
|
|
2018
Q2 | $314K | Buy |
+13,220
| New | +$280K | ﹤0.01% | 850 |
|
Other funds holding DXCM
VCM
VPM
ALPS Advisors's DXCM Position: Q1 2026 in Review
ALPS Advisors increased its DexCom (DXCM) stake by 0.86% in Q1 2026, buying an estimated $11K and bringing the position to 18,497 shares worth $1.16M. The position accounts for 0.01% of the portfolio, ranked #555.
ALPS Advisors first reported a position in DXCM in Q2 2018 and has held it in 32 quarters since. The position peaked at $2.79M in Q3 2021. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- ALPS Advisors held 18,497 shares of DexCom worth $1.16M as of Q1 2026.
- ALPS Advisors bought 158 DexCom shares in Q1 2026, an estimated $11K.
- DexCom made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #555 holding.
- ALPS Advisors first reported a position in DexCom in Q2 2018 and has held it in 32 quarters since.
- ALPS Advisors's DexCom position peaked at $2.79M in Q3 2021.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.